Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE vs R-ICE in Relapsed/Refractory Aggressive B-Cell NHL
NCT00006708Phase 3Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2000
- Primary completion
- Nov 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by SWOG Cancer Research Network. Started Oct 2000; status: terminated.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00006708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006708.